Centessa Pharmaceuticals plc (CNTA) Share Price Today, Stock Analysis, Annual Report | Value Research Centessa Pharmaceuticals plc (CNTA) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.

Centessa Pharmaceuticals plc (CNTA)

Download Stock Report

NASDAQ: CNTA

  • Price Change
  • Market Capitalisation market-capitalisation-info $430 Mln

  • 12 Month Earnings monthly-earning $-119 Mln
  • Price to Earnings price-to-earning --

Centessa Pharmaceuticals plc (CNTA) Share Price

$5.62

As on 02-Oct-2023 16:00 EDT

up-down-arrow $-0.85-13.14%

  • Prev Close info

    $6.47

  • Day's Openinfo

    $6.40

  • Today's Highinfo

    $6.40

  • Today's Lowinfo

    $5.18

  • Today's Volumeinfo

    217,909

Please wait...

Centessa Pharmaceuticals plc (CNTA) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Centessa Pharmaceuticals (CNTA)
81.29 -26.82 -9.21 39.80 -- -76.48 --
S&P BSE Sensex*
7.75 0.26 1.30 14.16 19.21 12.41 12.88
#
-- -- -- -- -- -- --
As on 02-Oct-2023  |  *As on 03-Oct-2023  |  #As on
2022
2018
Centessa Pharmaceuticals (CNTA)
-72.47 0.00
S&P BSE Sensex
4.44 5.87
S&P BSE Sensex
4.44 5.87

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Centessa Pharmaceuticals plc (CNTA) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Centessa Pharmaceuticals plc (CNTA)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        CEO & Director

        Dr. Saurabh Saha M.D., Ph.D.

        Principal Accounting Officer & CFO

        Dr. Gregory M. Weinhoff M.B.A., M.D., MBA

        Headquarters

        Altrincham

        FAQs for Centessa Pharmaceuticals plc (CNTA)

        The total asset value of Centessa Pharmaceuticals plc (CNTA) stood at $ 434 Mln as on 31-Mar-23

        The share price of Centessa Pharmaceuticals plc (CNTA) is $5.620000 (NASDAQ) as of 02-Oct-2023 16:00 EDT. Centessa Pharmaceuticals plc (CNTA) has given a return of 39.8% in the last 1 years.

        Centessa Pharmaceuticals plc (CNTA) has a market capitalisation of $ 430 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Centessa Pharmaceuticals plc (CNTA) is 0.98 times as on 02-Jun-2023, a -0.61% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Centessa Pharmaceuticals plc (CNTA) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Centessa Pharmaceuticals plc (CNTA) and enter the required number of quantities and click on buy to purchase the shares of Centessa Pharmaceuticals plc (CNTA).

        Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

        The CEO & director of Dr. Saurabh Saha M.D., Ph.D.. is Centessa Pharmaceuticals plc (CNTA), and CFO & Sr. VP is Dr. Gregory M. Weinhoff M.B.A., M.D., MBA.

        The promoters of Centessa Pharmaceuticals plc (CNTA) have pledged 0% of the total equity as on Mar-23.

        Centessa Pharmaceuticals plc (CNTA) Ratios
        Return on equity(%)
        -63.77
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.24
        Dividend yield(%)
        0

        No, TTM profit after tax of Centessa Pharmaceuticals plc (CNTA) was $-119 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $430.26 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-118.54 Mln
        • Cash date-information $346.23 Mln
        • Total Debt info $81.31 Mln
        • Insider's Holding 1.86%
        • Liquidity liquidity High
        • 52 Week range week-range $3.00 - 8.64
        • Shares outstanding share-outstanding 95,612,800

        About The Company

        • IPO Date 28-May-2021
        • CEO & Director Dr. Saurabh Saha M.D., Ph.D.
        • Principal Accounting Officer & CFO Dr. Gregory M. Weinhoff M.B.A., M.D., MBA
        • Listing key-listing NASDAQ: CNTA
        • Country United Kingdom
        • Headquarters headquarters Altrincham
        • Website website https://www.centessa.com
        • Business

          Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for...  the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon